Team Category: Advisors

Luc Debruyne

Mr. Luc Debruyne is a former Corporate Executive Team member of GlaxoSmithKline (GSK) where, over the course of a 27-year career, he rose to President of Global Vaccines..

He established GSK as the #1 Vaccines company worldwide, leading the launch of several successful vaccines including Shingrix, for shingles, and expanded the company’s US presence. Broad functional leadership experience includes research and development (R&D), commercial, manufacturing and quality operations. He currently is an active contributor in the global health arena and promotes sustainable business practices. He is a graduate of the University of Leuven (KULeuven – Belgium).

Dr. Mark Dybul

Dr. Mark Dybul is a professor in Georgetown University’s Department of Medicine and the co-director of their Center for Global Health Practice and Impact.

He has deep expertise in infectious disease and from 2012-2017 he served as Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. Prior to that he was appointed the U.S. Global AIDS Coordinator by then President George W. Bush, overseeing the implementation of the President’s Emergency Plan for AIDS Relief (PEPFAR). He holds an A.B. and M.D. from Georgetown University.

Dr. Drew Weissman

Dr. Drew Weissman is a professor of Medicine at the University of Pennsylvania’s Perelman School of Medicine.

Dr. Weissman co-discovered the ability of modified nucleosides in RNA to suppress activation of innate immune sensors and increase the translation of mRNA containing certain modified nucleosides. Dr. Weissman’s laboratory focuses on the study of RNA and innate immune system biology and the application of these findings to vaccine research, protein therapeutics, and gene therapy. He is also a member of The American Association of Immunologists, the American Federation for Clinical Research, and the Association of American Physicians. He received his graduate degrees from Boston University School of Medicine.